In its software, Lykos describes MDMA being a catalyst with the therapeutic system, And that's why it received so much interest. That's not expected to become just as much of a keep-up for other psychedelics, though. “The remainder of us are researching molecules that don't need the same degree of therapy,” states Kabir Nath, CEO of Compass Pat… Read More